Allogene Therapeutics Inc
NASDAQ:ALLO 4:00:00 PM EDT
| Market Cap (Intraday) | 718.15M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $5.16 |
| 50-Day MA | $6.46 |
| 200-Day MA | $9.89 |
Allogene Therapeutics Inc Stock, NASDAQ:ALLO
210 East Grand Avenue, South San Francisco, California 94080-4811
United States of America
Phone: +1.650.457.2700
Number of Employees: 361
Description
Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Its engineered T cells are allogeneic, which are derived from healthy donors for intended use in any patient. The company was founded by Arie S. Belldegrun, David D. Chang, David M. Tanen, and Joshua A. Kazam in November 2017 and is headquartered in South San Francisco, CA.